HER2-mediated effects on EGFR endosomal sorting: Analysis of biophysical mechanisms

被引:53
作者
Hendriks, BS
Wiley, HS
Lauffenburger, D
机构
[1] MIT, Dept Chem Engn, Cambridge, MA 02139 USA
[2] MIT, Dept Biol, Biol Engn Div, Cambridge, MA USA
[3] MIT, Ctr Canc Res, Cambridge, MA 02139 USA
[4] Pacific NW Natl Lab, Div Biol Sci, Richland, WA USA
关键词
D O I
10.1016/S0006-3495(03)74696-7
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Overexpression of HER2, a receptor-like tyrosine kinase and signaling partner for the epidermal growth factor receptor (EGFR), has been implicated in numerous experimental and clinical studies as promoting the progression of many types of cancer. One avenue by which HER2 overexpression may dysregulate EGFR-mediated cell responses, such as proliferation and migration, downstream of EGF family ligand binding, is by its modulation on EGFR endocytic trafficking dynamics. EGFR signaling is regulated by downregulation and compartmental relocalization arising from endocytic internalization and endosomal sorting to degradation versus recycling fates. HER2 overexpression influences both of these processes. At the endosomal sorting stage, increased HER2 levels elicit enhanced EGFR recycling outcomes, but the mechanism by which this transpires is poorly understood. Here, we determine whether alternative mechanisms for HER2-mediated enhancement of EGFR recycling can be distinguished by comparison of corresponding mathematical models to experimental literature data. Indeed, we find that the experimental data are clearly most consistent with a mechanism in which HER2 directly competes with EGFR for a stoichiometrically-limited quantity of endosomal retention components (ERCs), thereby reducing degradation of ERC-coupled EGFR. Model predictions based on this mechanism exhibited qualitative trends highly similar to data on the fraction of EGF/EGFR complexes sorted to recycling fate as a function of the amount of internalized EGF/EGFR complexes. In contrast, model predictions for alternative mechanisms-blocking of EGFR/ERC coupling, or altering EGF/EGFR dissociation-were inconsistent with the qualitative trends of the experimental data.
引用
收藏
页码:2732 / 2745
页数:14
相关论文
共 60 条
[1]   Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].
Agus, DB ;
Akita, RW ;
Fox, WD ;
Lewis, GD ;
Higgins, B ;
Pisacane, PI ;
Lofgren, JA ;
Tindell, C ;
Evans, DP ;
Maiese, K ;
Scher, HI ;
Sliwkowski, MX .
CANCER CELL, 2002, 2 (02) :127-137
[2]   The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions [J].
Alroy, I ;
Yarden, Y .
FEBS LETTERS, 1997, 410 (01) :83-86
[3]   A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization [J].
Baselga, J .
CANCER CELL, 2002, 2 (02) :93-95
[4]  
Baulida J, 1996, J BIOL CHEM, V271, P5251
[5]   c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells [J].
Brandt, BH ;
Roetger, A ;
Dittmar, T ;
Nikolai, G ;
Seeling, M ;
Merschjann, A ;
Nofer, JR ;
Dehmer-Möller, G ;
Junker, R ;
Assmann, G ;
Zaenker, KS .
FASEB JOURNAL, 1999, 13 (14) :1939-1949
[6]   Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking [J].
Burke, P ;
Schooler, K ;
Wiley, HS .
MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (06) :1897-1910
[7]  
CHAZIN VR, 1992, ONCOGENE, V7, P1859
[8]   OVEREXPRESSION OF THE HUMAN EGF RECEPTOR CONFERS AN EGF-DEPENDENT TRANSFORMED PHENOTYPE TO NIH 3T3 CELLS [J].
DIFIORE, PP ;
PIERCE, JH ;
FLEMING, TP ;
HAZAN, R ;
ULLRICH, A ;
KING, CR ;
SCHLESSINGER, J ;
AARONSON, SA .
CELL, 1987, 51 (06) :1063-1070
[9]   ERBB-2 IS A POTENT ONCOGENE WHEN OVEREXPRESSED IN NIH/3T3 CELLS [J].
DIFIORE, PP ;
PIERCE, JH ;
KRAUS, MH ;
SEGATTO, O ;
KING, CR ;
AARONSON, SA .
SCIENCE, 1987, 237 (4811) :178-182
[10]   HETERODIMERIZATION AND FUNCTIONAL INTERACTION BETWEEN EGF RECEPTOR FAMILY MEMBERS - A NEW SIGNALING PARADIGM WITH IMPLICATIONS FOR BREAST-CANCER RESEARCH [J].
EARP, HS ;
DAWSON, TL ;
LI, X ;
YU, H .
BREAST CANCER RESEARCH AND TREATMENT, 1995, 35 (01) :115-132